Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 6, 2008, Pages 455-457

  Swain, Sandra M ^a   Arezzo, Joseph C ^b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Epothilone; Ixabepilone; Microtubule inhibitor; Sensory neuropathy; Taxane; Vinca alkaloid

Indexed keywords

ALPHA TOCOPHEROL; AM 424; AMIFOSTINE; AMITRIPTYLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CASTOR OIL; CISPLATIN; DIMESNA; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GABAPENTIN; GLUTAMINE; IXABEPILONE; IXEMPRA; LAMOTRIGINE; LEVACECARNINE; MICROTUBULE INHIBITOR; NAVELBINE; NEUROPROTECTIVE AGENT; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

ADJUVANT THERAPY; ADVANCED CANCER; AUTONOMIC NEUROPATHY; BREAST CANCER; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FATIGUE; GAIT DISORDER; HEARING LOSS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERCEPTION DISORDER; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; REVIEW; SENSITIVITY AND SPECIFICITY; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SOLID TUMOR; SURVIVAL RATE; SYMPTOM; TINNITUS;

BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; POLYNEUROPATHIES; TUBULIN MODULATORS;

EID: 52949122818     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol. 2006;33:421-435.
2. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12:271-280.
3. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633-1642.
4. Makino H. Treatment and care of neurotoxicity from taxane anticancer agents. Breast Cancer. 2004;11:100-104.
5. Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer. 2007;7:543-549.
6. Meller K. Axoplasmic transport of horseradish peroxidase in single neurons of the dorsal root ganglion studied in vitro by microinjection. Cell Tissue Res. 1992;270:139-148.
7. Spencer PS. Biological principles of chemical neurotoxicity. In: Spencer PS, Schaumburg H, Ludolph AC, eds. Experimental and Clinical Neurotoxicology. 2nd ed. New York, NY: Oxford Press: 2000:3-54.
8. Schaumburg HH, Berger AR, Thomas PK. Anatomical Classification of Peripheral Nervous System Disorders. 2nd ed. Philadelphia, Penn: FA Davis Co; 1992:10-24.
9. Dougherty PM, Cata, JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109:132-142.
10. Roytta M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol. 1984;13:685-701.
11. Theiss C, Meller K. Taxol impairs anterograde axonal transport of micro-injected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res. 2000;299:213-224.
12. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
13. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11:4843-4850.
14. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006; 42:24-30.
15. Wampler MA, Rosenbaum EH. Chemotherapy-induced peripheral neuropathy fact sheet. Cancer Supportive Care Programs. http://www.cancersupportivecare.com/nervepain.php. Accessed June 29, 2007.
16. Bromberg MB. An approach to the evaluation of peripheral neuropathies. Semin Neurol. 2005;25:153-159.
17. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nursing. 2007;11: 361-376.
18. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5:65-71.
19. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63:1549-1563.
20. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute. 2006; 1-71.
21. Comis R. FCOG common toxicity criteria. Eastern Cooperative Oncology Group. www.ecog.org. Accessed December 6, 2007.
22. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210-215.
23. Lee JJ, Low JA, Croarkin E, et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.J Clin Oncol. 2006;24:2084-2091.
24. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Cancer. 1990; 66:1117-1123.
25. Gerritsen van der Hoop R. Incidence of neuropathy 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990; 66:1697-1702.
26. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000;11:69-72.
27. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer is women 60 years of age or older. Ann Oncol. 1999;10:397-402.
28. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorlbine in first-line advanced breast cancer chemotherapy: J Clin Oncol 1993;11:1245-1252.
29. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006;95:1161-1166.
30. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92:2267-2272.
31. Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64:1076-1077.
32. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: an overview. Cancer Treat Rev. 1996;22:127-142.
33. Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer. 2006;95:788-793.
34. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23:5542-5551.
35. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061-2068.
36. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14:1858-1867.
37. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995;13:2575-2581.
38. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol. 2004;22: Abstact. 512.
39. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999;17:3403-3411.
40. Blum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy fist metastatic breast cancer. J Clin Oncol. 2006;24:4384-4390.
41. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19: 4216-4223.
42. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94(suppl 1):A-3.
43. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. 2002;87:1210-l215.
44. Hudis C. Testing chemotherapy for breast cancer: timing is everything. J Clin Oncol. 2005;23:5434-5436.
45. Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489-494.
46. Taxotere [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2006.
47. Hilkens PH, Verweij J, Vecht CJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol. 1997;8:187-190.
48. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol. 2005;23:9120-9129.
49. Østerlind K, Sanchez JM, Zatloukal P, et al. Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. J Clin Oncol. 2005;23:647s. Abstract 7110.
50. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-1437.
51. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer. Breast Cancer Res Treat. 2005;94:S31-S32, Abstract 305.
52. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415-3420.
53. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399-3406.
54. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone analog, in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.
55. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-2734.
56. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007; 25:3421-3427.
57. Thomas E, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217.
58. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-2903.
59. O'Shaughnessy JA, Blum JL, Sandbach JF, et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat. 2004;88:S65. Abstract 1070.
60. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22:2587-2593.
61. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15:1358-1365.
62. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005;10:665-685.